127 related articles for article (PubMed ID: 29854301)
1. Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-Rα mutations.
Senkevitch E; Li W; Hixon JA; Andrews C; Cramer SD; Pauly GT; Back T; Czarra K; Durum SK
Oncotarget; 2018 Apr; 9(32):22605-22617. PubMed ID: 29854301
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of wild-type IL-7Rα promotes T-cell acute lymphoblastic leukemia/lymphoma.
Silva A; Almeida ARM; Cachucho A; Neto JL; Demeyer S; de Matos M; Hogan T; Li Y; Meijerink J; Cools J; Grosso AR; Seddon B; Barata JT
Blood; 2021 Sep; 138(12):1040-1052. PubMed ID: 33970999
[TBL] [Abstract][Full Text] [Related]
3. IL-7 receptor expression is frequent in T-cell acute lymphoblastic leukemia and predicts sensitivity to JAK inhibition.
Courtois L; Cabannes-Hamy A; Kim R; Delecourt M; Pinton A; Charbonnier G; Feroul M; Smith C; Tueur G; Pivert C; Balducci E; Simonin M; Angel LH; Spicuglia S; Boissel N; Andrieu GP; Asnafi V; Rousselot P; Lhermitte L
Blood; 2023 Jul; 142(2):158-171. PubMed ID: 37023368
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-7 signaling in human B cell precursor acute lymphoblastic leukemia cells and murine BAF3 cells involves activation of STAT1 and STAT5 mediated via the interleukin-7 receptor alpha chain.
van der Plas DC; Smiers F; Pouwels K; Hoefsloot LH; Löwenberg B; Touw IP
Leukemia; 1996 Aug; 10(8):1317-25. PubMed ID: 8709637
[TBL] [Abstract][Full Text] [Related]
5. IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia: An update.
Oliveira ML; Akkapeddi P; Ribeiro D; Melão A; Barata JT
Adv Biol Regul; 2019 Jan; 71():88-96. PubMed ID: 30249539
[TBL] [Abstract][Full Text] [Related]
6. CXCR4 allows T cell acute lymphoblastic leukemia to escape from JAK1/2 and BCL2 inhibition through CNS infiltration.
Walker KL; Rinella SP; Hess NJ; Turicek DP; Kabakov SA; Zhu F; Bouchlaka MN; Olson SL; Cho MM; Quamine AE; Feils AS; Gavcovich TB; Rui L; Capitini CM
Leuk Lymphoma; 2021 May; 62(5):1167-1177. PubMed ID: 33843403
[TBL] [Abstract][Full Text] [Related]
7. IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia.
Ribeiro D; Melão A; Barata JT
Adv Biol Regul; 2013 May; 53(2):211-22. PubMed ID: 23234870
[TBL] [Abstract][Full Text] [Related]
8. IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study.
Li Y; Buijs-Gladdines JG; Canté-Barrett K; Stubbs AP; Vroegindeweij EM; Smits WK; van Marion R; Dinjens WN; Horstmann M; Kuiper RP; Buijsman RC; Zaman GJ; van der Spek PJ; Pieters R; Meijerink JP
PLoS Med; 2016 Dec; 13(12):e1002200. PubMed ID: 27997540
[TBL] [Abstract][Full Text] [Related]
9. Growth of human T cell acute lymphoblastic leukemia lymphoblasts in NOD/SCID mouse fetal thymus organ culture.
Ma F; Manabe A; Wang D; Ito M; Kikuchi A; Wada M; Ito M; Ohara A; Hosoya R; Asano S; Tsuji K
Leukemia; 2002 Aug; 16(8):1541-8. PubMed ID: 12145696
[TBL] [Abstract][Full Text] [Related]
10. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
11. Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.
Peirs S; Frismantas V; Matthijssens F; Van Loocke W; Pieters T; Vandamme N; Lintermans B; Dobay MP; Berx G; Poppe B; Goossens S; Bornhauser BC; Bourquin JP; Van Vlierberghe P
Leukemia; 2017 Oct; 31(10):2037-2047. PubMed ID: 28074072
[TBL] [Abstract][Full Text] [Related]
12. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
13. MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia.
Canté-Barrett K; Spijkers-Hagelstein JA; Buijs-Gladdines JG; Uitdehaag JC; Smits WK; van der Zwet J; Buijsman RC; Zaman GJ; Pieters R; Meijerink JP
Leukemia; 2016 Sep; 30(9):1832-43. PubMed ID: 27174491
[TBL] [Abstract][Full Text] [Related]
14. Y-box-binding protein 1 contributes to IL-7-mediated survival signaling in B-cell precursor acute lymphoblastic leukemia.
Kariminia A; Ivison SM; Leung VM; Sung S; Couto N; Rozmus J; Rolf N; Narendran A; Dunn SE; Reid GS; Schultz KR
Oncol Lett; 2017 Jan; 13(1):497-505. PubMed ID: 28123588
[TBL] [Abstract][Full Text] [Related]
15. Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Leonard JT; Rowley JS; Eide CA; Traer E; Hayes-Lattin B; Loriaux M; Spurgeon SE; Druker BJ; Tyner JW; Chang BH
Sci Transl Med; 2016 Aug; 8(354):354ra114. PubMed ID: 27582059
[TBL] [Abstract][Full Text] [Related]
16. Impaired CD8 T cell memory and CD4 T cell primary responses in IL-7R alpha mutant mice.
Osborne LC; Dhanji S; Snow JW; Priatel JJ; Ma MC; Miners MJ; Teh HS; Goldsmith MA; Abraham N
J Exp Med; 2007 Mar; 204(3):619-31. PubMed ID: 17325202
[TBL] [Abstract][Full Text] [Related]
17. The IL-7R antagonist Lusvertikimab reduces leukemic burden in xenograft-ALL via antibody-dependent cellular phagocytosis.
Lenk L; Baccelli I; Laqua A; Heymann J; Reimer C; Dietterle A; Winterberg D; Mary C; Corallo F; Taurelle J; Narbeburu E; Neyton SL; Déramé M; Pengam S; Vogiatzi F; Bornhauser B; Bourquin JP; Raffel S; Dovhan V; Schüler T; Escherich G; den Boer ML; Boer JM; Wessels W; Peipp M; Alten J; Antić Ž; Bergmann AK; Schrappe M; Cario G; Brüggemann M; Poirier N; Schewe DM
Blood; 2024 Mar; ():. PubMed ID: 38518105
[TBL] [Abstract][Full Text] [Related]
18. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-2 gene-transduced human leukemic cells induce major histocompatibility complex-restricted and -unrestricted anti-leukemic effectors in mixed lymphocyte-tumor cultures.
Cignetti A; Guarini A; Gillio Tos A; Reato G; Foa R
Cancer Gene Ther; 2000 Feb; 7(2):167-76. PubMed ID: 10770624
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of co-operation of mutant
Winer H; Li W; Rodrigues G; Gower T; Meyer TJ; Hixon J; Durum SK
Haematologica; 2023 Nov; 109(6):1726-40. PubMed ID: 38031763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
